|
GATAD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.98779995083964E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.10189668290195E-11 |
| Normal-vs-Stage2 |
3.212200E-02 |
| Normal-vs-Stage3 |
2.03490000405537E-08 |
| Normal-vs-Stage4 |
2.90160000004924E-06 |
| Stage1-vs-Stage2 |
9.521900E-02 |
| Stage1-vs-Stage3 |
5.935400E-01 |
| Stage1-vs-Stage4 |
8.421600E-01 |
| Stage2-vs-Stage3 |
7.120300E-02 |
| Stage2-vs-Stage4 |
1.265410E-01 |
| Stage3-vs-Stage4 |
8.589800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5833999666981E-09 |
| Normal-vs-AfricanAmerican |
5.959700E-04 |
| Normal-vs-Asian |
4.90589999957436E-07 |
| Caucasian-vs-AfricanAmerican |
7.620200E-01 |
| Caucasian-vs-Asian |
8.147600E-01 |
| AfricanAmerican-vs-Asian |
8.740800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.90099999963778E-07 |
| Normal-vs-Female |
9.26419996272188E-09 |
| Male-vs-Female |
7.098400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.67659996996861E-10 |
| Normal-vs-Age(41-60Yrs) |
6.1705999976347E-08 |
| Normal-vs-Age(61-80Yrs) |
8.16519999999876E-05 |
| Normal-vs-Age(81-100Yrs) |
1.197700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.214800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.438000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.316600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.890600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.468100E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.164200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.222000E-04 |
| Classical-VS-Follicular |
5.761400E-03 |
| Classical-VS-Other |
6.760800E-01 |
| Classical-VS-Normal |
3.71769948159795E-10 |
| Tall-VS-Follicular |
2.13189999997976E-06 |
| Tall-VS-Other |
2.494100E-02 |
| Tall-VS-Normal |
4.9400483703721E-12 |
| Follicular-VS-Other |
3.144800E-01 |
| Follicular-VS-Normal |
1.829660E-02 |
| Other-VS-Normal |
3.442000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.72439999945873E-07 |
| Normal-vs-N1 |
5.73219999999708E-05 |
| N0-vs-N1 |
8.358000E-01 |
|
|
